September 4 Dinner Program, 7:00 p.m., Fleming's UTC/Mangrove Room.

If you are an NP working with Heart Failure patients and are associated with Sarasota Memorial Hospital (Main or Venice), this program is designed for you.  

Broadcast Date/Time: September 4th, 7pm EST / 9pm EST

Broadcast Title: “The Next Beat:  KERENDIA for Your Patients with HF With LVEF ≥40%”

Broadcast Objectives: 

1. Reinforce current unmet needs in patients with HF with LVEF ≥40%
2. The role of KERENDIA (Finerenone) as a selective, nonsteroidal mineralocorticoid receptor antagonist
3. KERENDIA (Finerenone) is a new core pillar in comprehensive care to reduce the risk of CV death and total HF events in patients with HF with LVEF ≥40%.

Please RSVP to:

Toni Gray Almgren, ISS (Institutional & Specialty Sales)

Cardiovascular Renal

Bayer U.S. LLC/Pharmaceuticals

100 Bayer Boulevard

Whippany NJ  07981, United States

Mobile: 859.576.9151

Work Cell: 941.875.3369

E-mail:  toni.almgren@bayer.com

Web:    http://www.bayer.us